Search results
13 lut 2021 · Shingrix (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as 2 doses given 2–6 months apart among adults aged ≥50 years. Clinical trials yielded efficacy of >90% for confirmed herpes zoster, but post-market performance has not been evaluated.
15 wrz 2021 · We used inverse probability of treatment weighting to improve cohort balance and marginal structural models to estimate hazard ratios. Results: We found a vaccine effectiveness of 70.1% (95% confidence interval [CI], 68.6-71.5) and 56.9% (95% CI, 55.0-58.8) for 2 and 1 doses, respectively.
8 sty 2024 · Shingrix is given in 2 doses given about 6 months apart. The study found 2 doses were 76% effective against shingles, while 1 dose was 64% effective. Over the 4-year period, the 2-dose regimen waned little while the single dose waned more, dropping to 52% after the third year.
25 paź 2018 · In this systematic review and network meta-analysis we compared the efficacy, effectiveness, and safety of the live attenuated herpes zoster vaccine with the adjuvant recombinant subunit vaccine, placebo, or no vaccine in those aged 50 years and older.
1 kwi 2024 · The CDC recommends adults ages 50 and older get two doses of the recombinant zoster vaccine (Shingrix), with the doses separated by two to six months, to prevent shingles. But how long can it offer protection?
9 wrz 2021 · Recombinant zoster vaccine effectiveness against herpes zoster was high in a real-world setting. Given the low vaccine coverage and high effectiveness, a major public health effort is needed to identify and address barriers to vaccination and increase immunization rates.
The vaccine effectiveness against herpes zoster for patients with chronic obstructive pulmonary disease was 67·0% (95% CI 52·0–82·0%). This study also reported the vaccine effectiveness for ZVL against herpes zoster among people with asthma (vaccine effectiveness 68·0%, 58·0–78·0).
